Previous close | 2.0100 |
Open | 2.0100 |
Bid | 1.4400 |
Ask | 1.7000 |
Strike | 95.00 |
Expiry date | 2025-01-17 |
Day's range | 2.0100 - 2.0100 |
Contract range | N/A |
Volume | |
Open interest | 2k |
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a solid underlying business. It's a Dividend King with 52 consecutive years of payout hikes -- if you include the time it spent as a unit of Abbott Laboratories.